290 related articles for article (PubMed ID: 9492152)
1. Serum concentration of soluble Fas in patients with autoimmune thyroid diseases.
Shimaoka Y; Hidaka Y; Okumura M; Takeoka K; Tada H; Amino N
Thyroid; 1998 Jan; 8(1):43-7. PubMed ID: 9492152
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers.
Myśliwiec J; Okota M; Nikołajuk A; Górska M
Adv Med Sci; 2006; 51():119-22. PubMed ID: 17357290
[TBL] [Abstract][Full Text] [Related]
3. Increased serum soluble Fas in patients with Graves' disease.
Hiromatsu Y; Bednarczuk T; Soyejima E; Miyake I; Yang D; Fukazawa H; Nonaka K
Thyroid; 1999 Apr; 9(4):341-5. PubMed ID: 10319938
[TBL] [Abstract][Full Text] [Related]
4. Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis.
Okumura M; Hidaka Y; Kuroda S; Takeoka K; Tada H; Amino N
J Clin Endocrinol Metab; 1997 Jun; 82(6):1757-60. PubMed ID: 9177377
[TBL] [Abstract][Full Text] [Related]
5. Opposite changes in serum soluble CD8 in patients at the active stages of Graves' and Hashimoto's diseases.
Watanabe M; Amino N; Hochito K; Watanabe K; Kuma K; Iwatani Y
Thyroid; 1997 Oct; 7(5):743-7. PubMed ID: 9349577
[TBL] [Abstract][Full Text] [Related]
6. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.
Mariotti S; Caturegli P; Barbesino G; Marinò M; Del Prete GF; Chiovato L; Tonacchera M; De Carli M; Pinchera A
Clin Endocrinol (Oxf); 1992 Nov; 37(5):415-22. PubMed ID: 1486691
[TBL] [Abstract][Full Text] [Related]
7. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response.
Mysliwiec J; Oklota M; Nikolajuk A; Waligorski D; Gorska M
Immunol Invest; 2007; 36(3):247-57. PubMed ID: 17558708
[TBL] [Abstract][Full Text] [Related]
8. Circulating nuclear matrix protein in Graves' disease.
Hara H; Morita Y; Sato R; Ban Y
Endocr J; 2002 Jun; 49(3):343-7. PubMed ID: 12201219
[TBL] [Abstract][Full Text] [Related]
9. [Increased serum soluble Fas ligand in hyperthyroid Graves' disease].
Takeda K; Ohara E; Kaneda T; Hashimoto K; Sasaki M
Rinsho Byori; 1999 Oct; 47(10):961-5. PubMed ID: 10590671
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease.
Feldkamp J; Pascher E; Schott M; Goretzki P; Seissler J; Scherbaum WA
J Clin Endocrinol Metab; 2001 Sep; 86(9):4250-3. PubMed ID: 11549657
[TBL] [Abstract][Full Text] [Related]
11. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
12. Increased serum concentration of interleukin-12 in patients with silent thyroiditis and Graves' disease.
Hidaka Y; Okumura M; Fukata S; Shimaoka Y; Takeoka K; Tada H; Kuma K; Amino N
Thyroid; 1999 Feb; 9(2):149-53. PubMed ID: 10090314
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of Fas-mediated apoptosis in both thyrocyte and lymphocyte cellular compartments correlates with opposite phenotypic manifestations of autoimmune thyroid disease.
Giordano C; Richiusa P; Bagnasco M; Pizzolanti G; Di Blasi F; Sbriglia MS; Mattina A; Pesce G; Montagna P; Capone F; Misiano G; Scorsone A; Pugliese A; Galluzzo A
Thyroid; 2001 Mar; 11(3):233-44. PubMed ID: 11327614
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human thyrotropin (TSH) receptor in a radioreceptor assay for the measurement of TSH receptor autoantibodies.
Filetti S; Foti D; Costante G; Rapoport B
J Clin Endocrinol Metab; 1991 May; 72(5):1096-101. PubMed ID: 2022709
[TBL] [Abstract][Full Text] [Related]
15. Differential autoantibody responses to thyroid peroxidase in patients with Graves' disease and Hashimoto's thyroiditis.
Bermann M; Magee M; Koenig RJ; Kaplan MM; Arscott P; Maastricht J; Johnson J; Baker JR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1098-101. PubMed ID: 8408460
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic significance of serum concentrations of soluble Fas ligand (sFasL) in children with autoimmune thyroid disease.
Mikos H; Mikos M; Niedziela M
Autoimmunity; 2017 May; 50(3):192-198. PubMed ID: 28276714
[TBL] [Abstract][Full Text] [Related]
17. Hashimoto's thyroiditis following Graves' disease.
Umar H; Muallima N; Adam JM; Sanusi H
Acta Med Indones; 2010 Jan; 42(1):31-5. PubMed ID: 20305330
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of Fas system apoptotic molecules in peripheral lymphocytes from patients with Graves' disease and Hashimoto's thyroiditis.
Fountoulakis S; Vartholomatos G; Kolaitis N; Frillingos S; Philippou G; Tsatsoulis A
Eur J Endocrinol; 2008 Jun; 158(6):853-9. PubMed ID: 18505906
[TBL] [Abstract][Full Text] [Related]
19. Thyroid peroxidase activity-inhibiting immunoglobulins in patients with autoimmune thyroid disease.
Okamoto Y; Hamada N; Saito H; Ohno M; Noh J; Ito K; Morii H
J Clin Endocrinol Metab; 1989 Apr; 68(4):730-4. PubMed ID: 2921308
[TBL] [Abstract][Full Text] [Related]
20. Normal immunoregulation of in vitro antibody secretion in autoimmune thyroid disease.
MacLean DB; Miller KB; Brown R; Reichlin S
J Clin Endocrinol Metab; 1981 Oct; 53(4):801-5. PubMed ID: 6457056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
